BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 15, 2025
Breaking News: Commission proposes ‘radical overhaul’ of obesity definition, diagnosis
See today's BioWorld Science
Home
» Dual TRPV6/AR inhibitor strongly reduces prostate tumor growth
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Dual TRPV6/AR inhibitor strongly reduces prostate tumor growth
Sep. 6, 2024
No Comments
The TRPV6 calcium channel is overexpressed in several types of cancer deriving from epithelia where calcium control is unbalanced, such as prostate, colon or breast cancer, among others.
BioWorld Science
Conferences
Cancer